Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewQNZ 46 is a GluN2C/GluN2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for GluN2D, GluN2C, GluN2A, GluN2B, and GluR1, respectively). Requires binding of glutamate to the GluN2 subunit.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
QNZ 46 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 443.41 |
Formula | C24H17N3O6 |
Storage | Store at RT |
Purity | ≥98% (HPLC) |
CAS Number | 1237744-13-6 |
PubChem ID | 46861929 |
InChI Key | GNLVJIICVWDSNI-LFYBBSHMSA-N |
Smiles | O=C2C1=CC(OC)=CC=C1N=C(/C=C/C4=CC([N+]([O-])=O)=CC=C4)N2C3=CC=C(C(O)=O)C=C3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 4.43 | 10 with gentle warming |
The following data is based on the product molecular weight 443.41. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 22.55 mL | 112.76 mL | 225.52 mL |
0.5 mM | 4.51 mL | 22.55 mL | 45.1 mL |
1 mM | 2.26 mL | 11.28 mL | 22.55 mL |
5 mM | 0.45 mL | 2.26 mL | 4.51 mL |
References are publications that support the biological activity of the product.
Mosley et al (2010) Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-MthD.-aspartate receptor antagonists. J.Med.Chem. 53 5476 PMID: 20684595
Hansen and Traynelis (2011) Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J.Neurosci. 31 3650 PMID: 21389220
If you know of a relevant reference for QNZ 46, please let us know.
Keywords: QNZ 46, QNZ 46 supplier, QNZ46, Glu, NR2C, NR2D, antagonists, glutamate, NMDA, receptors, GluN2C, GluN2D, Receptors, 4801, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for QNZ 46 include:
Brancaccio et al (2017) Astrocytes Control Circadian Timekeeping in the Suprachiasmatic Nucleus via Glutamatergic Signaling. Neuron 93 1420 PMID: 28285822
Robert H et al (2020) Astrocytes Are Required for Oligodendrocyte Survival and Maintenance of Myelin Compaction and Integrity. Front Cell Neurosci 14 74 PMID: 32300294
Do you know of a great paper that uses QNZ 46 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review QNZ 46 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.